Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503724 · ClinicalTrials.gov registry record · Phase 1
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00503724 is a Phase 1 study that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 32 participants.
The verdict
NCT00503724, a Phase 1 study, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin in treating young patients with refractory primary brain tumors.
Interventions
- DRUG enzastaurin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503724
The ClinicalTrials.gov registry entry for NCT00503724 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which enzastaurin hydrochloride is the first listed.
NCT00503724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503724 about?
NCT00503724 is a clinical study titled "Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors". RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin in treating young patients with refractory primary brain tu...
What is the current status of trial NCT00503724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2007-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00503724?
The interventions under investigation include: enzastaurin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00503724?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.